22157.jpg
Global Vertigo Treatment Market Forecast to Reach $1.6 Billion by 2030, Driven by the Rise in Benign Paroxysmal Positional Vertigo Prevalence
May 16, 2024 07:52 ET | Research and Markets
Dublin, May 16, 2024 (GLOBE NEWSWIRE) -- The "Vertigo Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The...
22157.jpg
Global Parkinson Disease Market Projected to Reach $8.8 Billion by 2030, Driven by Advancements and Growing Demand for Effective Treatments
March 28, 2024 11:41 ET | Research and Markets
Dublin, March 28, 2024 (GLOBE NEWSWIRE) -- The "Parkinson Disease Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. ...
motion-sickness-treatment-market-size.jpg
Global $481 Million Motion Sickness Treatment Market, 2023-2029: Rising Demand Among Millennial Travelers for Distinctive & Exclusive Travel Experiences Driving the Market
June 26, 2023 05:18 ET | Research and Markets
Dublin, June 26, 2023 (GLOBE NEWSWIRE) -- The Global Motion Sickness Treatment Market, 2023-2029 report has been added to ResearchAndMarkets.com's offering.The Global Motion Sickness Treatment...
Global Cerebral Palsy Treatment Market
Global Cerebral Palsy Treatment Market Report to 2030 - Featuring Merz Pharmaceuticals, Pfizer, Bayer and Johnson & Johnson Among Others
May 16, 2022 07:13 ET | Research and Markets
Dublin, May 16, 2022 (GLOBE NEWSWIRE) -- The "Cerebral Palsy Treatment Market by Drug Type, Disease Type, Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030" report...
22157.jpg
2021 U.S. Parkinson's Disease Epidemiology Report: 10-year Forecasts of Parkinson's Disease Epidemiology
August 23, 2021 04:18 ET | Research and Markets
Dublin, Aug. 23, 2021 (GLOBE NEWSWIRE) -- The "Parkinson's Disease - US Epidemiology Forecast to 2030" drug pipelines has been added to ResearchAndMarkets.com's offering. The report delivers an...
Dermira_Logo_RGB_R4V2_M01.jpg
Newly Published Nonclinical Data Highlight the Role of Olumacostat Glasaretil in Sebum Inhibition
June 26, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 26, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Appointment of Ian Clements as Vice President, Investor Relations
June 06, 2017 07:30 ET | Dermira, Inc.
MENLO PARK, Calif., June 06, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira to Present at Jefferies 2017 Global Healthcare Conference
May 30, 2017 16:05 ET | Dermira, Inc.
MENLO PARK, Calif., May 30, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Announces Closing of 3.00% Convertible Senior Notes Offering
May 16, 2017 16:01 ET | Dermira, Inc.
MENLO PARK, Calif., May 16, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the closing of its previously announced offering of 3.00% Convertible Senior Notes due 2022 (the...
Dermira_Logo_RGB_R4V2_M01.jpg
Dermira Prices Offering of $250 Million of 3.00% Convertible Senior Notes
May 10, 2017 21:32 ET | Dermira, Inc.
MENLO PARK, Calif., May 10, 2017 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM) announced today the pricing of its offering of $250,000,000 aggregate principal amount of 3.00% Convertible Senior...